Search Results for “AstraZeneca” – Page 25 – media

Orphan Designation Granted to AZ and MSD’s Neurofibromatosis Drug

AstraZeneca and MSD's neurofibromatosis type 1 (NF1) drug, selumetinib, a MEK 1/2 inhibitor, receives orphan designation by the EMA.
- Source: PharmaTimes
- 756
- August 7, 2018
AstraZeneca neurofibromatosis New Approvals
Johnson & Johnson under Justice Department Scrutiny for Funding Iraqi Terrorism

After the disclosure from AstraZeneca that it’s under Justice Department scrutiny for illegally funding Iraqi terrorism, Roche and Johnson & Johnson revealed similar inquiries from the agency.
- Source: FiercePharma
- 557
- August 6, 2018
Company Insight lawsuit pharmaceutical company
Filing Lawsuit Against Drugmakers for Funding Terrorism

Last year, around 100 veterans filed a bombshell lawsuit against several drugmakers, by accusing that they funded terrorism by paying high bribes to win contracts with the Iraqi Ministry of Health. At present, the Department of Justice is investigating similar accusations, as per AstraZeneca securities filing which says that it's part of the probe.
- Source: FiercePharma
- 1,046
- August 3, 2018
AstraZeneca Company Insight pharmaceutical
Q2 Results Roundup Released

Some of the leading pharma companies have released their second-quarter results of 2018
- Source: PharmaTimes
- 579
- July 31, 2018
Market Views pharmaceutical company
Enquiry for Nucala in COPD

Nucala (mepolizumab) was first approved as the first anti-IL5 treatment for adults and adolescents with severe asthma accompanied by eosinophilic phenotype in the United States during November 2015. Later it was approved to treat eosinophilic granulomatosis with polyangiitis (EGPA).
- Source: BioPharmaDive
- 773
- July 26, 2018
COPD GSK New Approvals
Novartis Shuts Down Its Antimicrobial Research

Despite the looming crises, Novartis will be shutting down antimicrobial research at its Novartis Institutes for Biomedical Research campus in Emeryville, California. There will be a loss of 140 jobs and the current projects will be put up for sale. This company was working on phase 2 clinical trial of LYS228 against complicated urinary tract infections and complicated intra-abdominal infections. The work on anti-dengue drugs and anti-malaria drugs (KAF156 and KAE609) were already in pipeline.
- Source: Fierce Biotech
- 731
- July 16, 2018
AMR antibiotic resistance Company Insight
China’s Drastic Reduction in Cancer Drug Price

The newly formed health insurance administration in China intend to deepen discounts on cancer drugs which were already on its National Reimbursement Drug List (NRDL) based on public bidding and procurement based on cancer therapies. In the meantime, officials will start enlisting negotiations for treatments which were not included on the coverage list.
- Source: FiercePharma
- 812
- July 11, 2018
cancer China pharmaceutical drugs Policies
FDA Anounces Restricted use of Keytruda & Tecentriq Against Bladder Cancer

Keytruda is now allowed only for the patients whose tumor expression levels of the biomarker PD-L1 meet a combined positive score of 10 or higher. Tecentriq can only be used where PD-L1 immune cells can cover only 5% or more of their tumor area.
- Source: FiercePharma
- 777
- June 26, 2018
bladder cancer Company Insights Merck Roche
One More Approval for Merck’s Keytruda

On Wednesday, a day after Keytruda got the thumbs up for cervical cancer, the drug was approved for treatment of a rare form of non-Hodgkins lymphoma patients who cancer returned after at least two previous treatment lines. Last year, Keytruda also got an indication for classical Hodgkin lymphoma.
- Source: Fierce Pharma
- 716
- June 15, 2018
cancer Merck New Approvals non-Hodgkin lymphoma
Lynparza and Zytiga Combo Effective Against Prostate Cancer

Along with new drug partner Merck, the British drugmaker displayed results showing that adding Lynparza to Johnson & Johnson prostate cancer fighter Zytiga was a more potent disease-fighter than Zytiga alone. As compared to a time-frame of 8.2 months for solo Zytiga, the combo effectively prevented disease progression for 13.8 months.
- Source: Ddu
- 764
- June 6, 2018
AstraZeneca Clinical Trials Company Insight prostate cancer

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.